Boundless Bio, Inc. (BOLD)
$2.85-$0.03 (-1.05%) Today
Latest BOLD Insider Trades
Kevin Tang - 10% OwnerOpen-market sale
Kevin Tang - 10% OwnerKevin TangKevin TangKevin TangKevin TangKevin TangKevin TangKevin TangBoundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 22 | 611,423 | $1.52M |
| Open-market sale | 3 | 50,300 | $134K |
| Grant or award | 4 | 144,000 | |
| Option exercise | 4 | 64,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
19 Form 4 filings on record, the earliest from Jun 23, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Kevin Tang - 10% Owner | Open-market sale | Common Stock | 18,300 | $2.97 | $54K | |
| Kevin Tang | Open-market purchase | Common Stock | 265 | $2.44 | $647 | |
| Kevin Tang | Open-market purchase | Common Stock | 1,623 | $2.44 | $4K | |
| Kevin Tang | Open-market purchase | Common Stock | 2,975 | $2.44 | $7K | |
| Kevin Tang | Open-market purchase | Common Stock | 43,878 | $2.43 | $107K | |
| Kevin Tang | Open-market purchase | Common Stock | 1,600 | $2.44 | $4K | |
| Kevin Tang | Open-market purchase | Common Stock | 18,491 | $2.44 | $45K | |
| Kevin Tang | Open-market purchase | Common Stock | 7 | $2.48 | $17 | |
| Kevin Tang | Open-market purchase | Common Stock | 43,367 | $2.43 | $105K | |
| Kevin Tang | Open-market purchase | Common Stock | 48,211 | $2.42 | $117K | |
| Kevin Tang | Open-market purchase | Common Stock | 27,062 | $2.49 | $67K | |
| Kevin Tang | Open-market purchase | Common Stock | 15,810 | $2.48 | $39K | |
| Kevin Tang | Open-market purchase | Common Stock | 14,338 | $2.46 | $35K | |
| Keith Crandell - 10% Owner | Option exercise | Common Stock | 16,000 | $1.03 | $16K | |
| Keith Crandell - 10% Owner | Open-market sale | Common Stock | 16,000 | $2.49 | $40K | |
| Keith Crandell - 10% Owner | Option exercise | Stock Option (right to buy) | 16,000 | $0.00 | - | |
| ARCH Venture Fund IX, L.P. - 10% Owner | Option exercise | Common Stock | 16,000 | $1.03 | $16K | |
| ARCH Venture Fund IX, L.P. - 10% Owner | Open-market sale | Common Stock | 16,000 | $2.49 | $40K | |
| ARCH Venture Fund IX, L.P. - 10% Owner | Option exercise | Stock Option (right to buy) | 16,000 | $0.00 | - | |
| Kevin Tang | Open-market purchase | Common Stock | 25,930 | $2.54 | $66K | |
| Kevin Tang | Open-market purchase | Common Stock | 100 | $2.50 | $250 | |
| Kevin Tang | Open-market purchase | Common Stock | 71,612 | $2.49 | $178K | |
| Kevin Tang | Open-market purchase | Common Stock | 9,821 | $2.49 | $24K | |
| Kevin Tang | Open-market purchase | Common Stock | 145,880 | $2.48 | $362K | |
| Kevin Tang | Open-market purchase | Common Stock | 510 | $2.56 | $1K | |
| Kevin Tang | Open-market purchase | Common Stock | 75,047 | $2.55 | $191K | |
| Kevin Tang | Open-market purchase | Common Stock | 134 | $2.54 | $340 | |
| Kevin Tang | Open-market purchase | Common Stock | 63,985 | $2.47 | $158K | |
| Kevin Tang | Open-market purchase | Common Stock | 777 | $2.48 | $2K | |
| Nancy Whiting | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
 Jonathan E. Lim | Grant or award | Stock Option (right to buy) | 48,000 | $0.00 | - | |
| James Christensen | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
 Jennifer Lew | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
 Jessica Oien - Officer | Grant or award | Stock Option (right to buy) | 220,000 | $0.00 | - | |
 Christian Hassig - Officer | Grant or award | Stock Option (right to buy) | 230,000 | $0.00 | - | |
 Robert Doebele - Officer | Grant or award | Stock Option (right to buy) | 230,000 | $0.00 | - | |
| Zachary Hornby - Officer | Grant or award | Stock Option (right to buy) | 600,000 | $0.00 | - | |
 David A. Hinkle - Officer | Grant or award | Stock Option (right to buy) | 140,000 | $0.00 | - | |
| Jonathan E. Lim | Grant or award | Stock Option (right to buy) | 24,000 | $0.00 | - |
Boundless Bio, Inc. (BOLD) had 13 insider filings in the last 90 days, with the most recent on 2026-08-28. The full record for BOLD runs to 19 Form 4 filings, the earliest from 2025-06-23. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
22 insider purchases of BOLD were filed in the last 90 days, totaling $1.52M.
3 insider sales of BOLD were filed in the last 90 days, totaling $134K.
This page tracks BOLD Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add BOLD to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
